NEW YORK – Danaher subsidiary Beckman Coulter Life Sciences and Pillar Biosciences announced an agreement on Tuesday to develop next-generation sequencing-based tests for cancer.

纽约-达纳赫子公司贝克曼库尔特生命科学公司和Pillar Biosciences于星期二宣布达成协议，开发基于下一代测序的癌症检测方法。

Pillar Biosciences will develop a series of tests for use on Beckman Coulter's Biomek NGeniuS Next Generation Library Preparation System, initially focusing on five commercially available solid tumor liquid biopsy and hematology panels from Pillar, Beckman Coulter said in a statement. The OncoReveal Myeloid, OncoReveal Solid Tumor v2, OncoReveal Multi-Cancer plus CNV, OncoReveal Solid Tumor 22 Gene, and OncoReveal Core LBx tests will be designed for the Biomek system and be available to customers via an electronic application library..

Pillar Biosciences将开发一系列用于Beckman Coulter的Biomek NGeniuS下一代文库制备系统的测试，最初侧重于Beckman Coulter在声明中说的Pillar的五个市售实体肿瘤液体活检和血液学小组。OncoReveal髓样，OncoReveal实体瘤v2，OncoReveal多癌症加CNV，OncoReveal实体瘤22基因和OncoReveal核心LBx测试将为Biomek系统设计，并可通过电子应用程序库提供给客户。。

Financial and other terms of the deal were not disclosed.

没有披露交易的财务和其他条款。

'Combining the simplicity of our NGS library preparation technology with the automation capabilities of the Biomek NGeniuS System will significantly reduce error, assay costs, and hands-on time, helping ensure more oncology researchers get the results they need faster, with lower costs and greater efficiency,' Pillar Biosciences CEO Randy Pritchard said in a statement. .

“将我们的NGS图书馆准备技术的简单性与Biomek NGeniuS系统的自动化功能相结合，将显着减少错误，化验成本和动手时间，帮助确保更多的肿瘤学研究人员获得他们需要的结果，成本更低，更高效率，“Pillar Biosciences首席执行官Randy Pritchard在一份声明中说。 .

The Biomek system uses software that allows any batch size between four and 24 samples to be set up and monitored remotely, Beckman Coulter noted. The automated library preparation platform includes a reagent input carousel, an integrated thermal cycler, and a labware transport system.

Beckman Coulter指出，Biomek系统使用的软件允许远程设置和监控4到24个样品之间的任何批量大小。自动化图书馆准备平台包括试剂输入转盘，集成热循环仪和实验室运输系统。

Last year, the companies announced an application development agreement for next-generation sequencing solutions.

去年，这些公司宣布了下一代测序解决方案的应用程序开发协议。